Cita APA

Yaeger, R., Siu, L., Ducreux, M., Van Cutsem, E., DELORD, J., Tabernero, J., & Elez, E. (2023). Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer.

Citación estilo Chicago

Yaeger, Rona, Lillian Siu, Michel Ducreux, Eric Van Cutsem, Jean-Pierre DELORD, Josep Tabernero, y Elena Elez. Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer. 2023.

Cita MLA

Yaeger, Rona, et al. Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer. 2023.